Squarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE)

Squarepoint Ops LLC increased its holdings in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) by 250.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,431 shares of the company's stock after buying an additional 12,451 shares during the quarter. Squarepoint Ops LLC owned 0.12% of Neurogene worth $398,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in NGNE. Virtus ETF Advisers LLC raised its stake in shares of Neurogene by 45.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company's stock valued at $73,000 after purchasing an additional 989 shares during the period. Rhumbline Advisers raised its stake in shares of Neurogene by 9.2% in the 4th quarter. Rhumbline Advisers now owns 15,704 shares of the company's stock valued at $359,000 after purchasing an additional 1,326 shares during the period. Wells Fargo & Company MN raised its stake in shares of Neurogene by 34.5% in the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company's stock valued at $124,000 after purchasing an additional 1,397 shares during the period. Barclays PLC raised its stake in shares of Neurogene by 18.0% in the 4th quarter. Barclays PLC now owns 17,533 shares of the company's stock valued at $401,000 after purchasing an additional 2,674 shares during the period. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of Neurogene in the 4th quarter valued at about $71,000. Institutional investors and hedge funds own 52.37% of the company's stock.

Insider Buying and Selling

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. The trade was a 5.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Stuart Cobb sold 6,797 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $15.15, for a total value of $102,974.55. Following the sale, the insider now owns 20,794 shares of the company's stock, valued at approximately $315,029.10. This represents a 24.63% decrease in their position. The disclosure for this sale can be found here. 11.64% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

NGNE has been the topic of several recent research reports. Robert W. Baird downgraded Neurogene from an "outperform" rating to a "neutral" rating and dropped their price target for the company from $38.00 to $24.00 in a research note on Friday, May 16th. Baird R W cut Neurogene from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th. HC Wainwright decreased their price objective on Neurogene from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. BMO Capital Markets raised their price objective on Neurogene from $16.00 to $22.00 and gave the company an "outperform" rating in a report on Tuesday, May 20th. Finally, William Blair restated an "outperform" rating on shares of Neurogene in a report on Tuesday, March 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Neurogene has an average rating of "Moderate Buy" and a consensus price target of $44.60.

Neurogene Stock Performance

Neurogene stock opened at $22.92 on Friday. Neurogene Inc. has a 52 week low of $6.88 and a 52 week high of $74.49. The stock has a market capitalization of $326.89 million, a P/E ratio of -5.27 and a beta of 1.57. The stock has a 50-day simple moving average of $14.43 and a 200 day simple moving average of $17.54.

Neurogene (NASDAQ:NGNE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by ($0.03). Research analysts forecast that Neurogene Inc. will post -4.27 earnings per share for the current year.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Want to see what other hedge funds are holding NGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurogene Inc. (NASDAQ:NGNE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.